Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Mark J. Foley, a director at Glaukos Corp (NYSE:GKOS), recently sold 20,687 shares of the company’s common stock. The sale, executed on February 26, 2025, occurred at a weighted average price of $120.72 per share, bringing the total transaction value to approximately $2.5 million. The transaction comes as the stock, currently valued at a market cap of $6.75 billion, has declined 21% year-to-date, though it maintains a 31% gain over the past year. According to InvestingPro analysis, the stock appears overvalued at current levels.
In addition to the sale, Foley also exercised stock options on the same day. He acquired 25,000 shares at $32.00 per share and 15,000 shares at $24.69 per share, resulting in a total acquisition value of approximately $1.17 million. Discover more insights about GKOS and access detailed Fair Value analysis with InvestingPro, which offers 10+ additional exclusive tips for this stock. Following these transactions, Foley holds 54,249 shares of Glaukos common stock directly.
In other recent news, Glaukos Corporation reported its fourth-quarter 2024 earnings, showcasing a revenue increase of 28% year-over-year to $105.5 million, surpassing expectations. However, the company reported an earnings per share (EPS) of -$0.40, slightly missing forecasts. Glaukos also provided guidance for 2025, projecting net sales between $475 million and $485 million, indicating a growth of 24% to 26%. In a separate development, the FDA has set a review date for Glaukos’ keratoconus drug, Epioxa, with a decision expected by October 2025. Truist Securities maintained a Buy rating on Glaukos, with a price target of $185, highlighting the potential of the iDose product, which saw a significant increase in revenue. Meanwhile, BTIG adjusted its price target for Glaukos to $155 from $157, citing strong glaucoma revenue but challenges in corneal health revenue. The company’s iDose product is anticipated to play a crucial role in supporting growth, with projections for its revenue in 2025 increased to approximately $117 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.